



LKT Laboratories, Inc.

Cediranib

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID C1613

CAS No. 288383-20-0

Chemical Name

Synonym AZD2171


Formula C₂₅H₂₇FN₄O₃

Formula Wt. 450.51

Melting Point

Purity ≥98%

Solubility DMSO to 90 mg/ml



Bulk quantities available upon request

Product ID **Size**

C1613 25 mg

C1613 100 mg

C1613 250 mg

Store Temp Ambient

Ship Temp Ambient

Description Cediranib is a pan-VEGFR inhibitor that displays anticancer chemotherapeutic and anti-angiogenic activities. Cediranib is currently in clinical trials and displays activity against a wide variety of cancers. In an animal model of intestinal cancer, cediranib decreases lesion number and polyp size, and in a separate animal model of brain metastasis, cediranib decreases tumor vascular bed volume.

References Kummar S, Allen D, Monks A, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol. 2013 Jun 20;31(18):2296-302. PMID: 23630200.

JuanYin J, Tracy K, Zhang L, et al. Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin Exp Metastasis. 2009;26(5):403-14. PMID: 19277878.

Goodlad RA, Ryan AJ, Wedge SR, et al. Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. Carcinogenesis. 2006 Oct;27(10):2133-9. PMID: 16782971.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.